Aktuellt
SENASTE
Cantargia reported its Q2 numbers this morning with an operating loss of SEK -86.6m, 3% less negative than our estimates and up 132% from last year (SEK -37.7m). The improved y/y loss was expected, as the company has initiated and applied for several studies to broaden its oncology pipeline during the quarter. The company did not change its view on the cash spending onwards and, as it guided for last quarter, the cash and cash equivalents (currently at SEK 760.7m) will last at least until the end of 2022.
LÄS MER
